Dr. Kamath on the Inclusion of Underrepresented Groups in Clinical Trials

Video

In Partnership With:

Suneel Kamath, MD, discusses the importance of including underrepresented patient populations in clinical trials.

Suneel Kamath, MD, assistant professor of Medicine, the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses the importance of including underrepresented patient populations in clinical trials.

Including underrepresented groups in clinical trials helps those patients become voices for their communities at large by advocating for additional participation, Kamath says. Patients from underserved communities who do enroll in clinical trials benefit the most, and they can serve as examples of how clinical trials can provide necessary treatment, Kamath explains.

Clinical trials are a beneficial avenue for patients to voice their opinions, receive beneficial treatment, and help advocate for more inclusion, Kamath concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD